Alvio Labs — January 1 to March 31, 2026
Net Profit (Q1)
-€4,226.52
Loss recorded
Cash Balance
€116.00
-78.2% vs prior year
Monthly Burn Rate
€398
Based on Q1 OpEx
Cash Runway
< 1 Week
Critical
Alvio Labs recorded a net loss of €4,226.52 for the first quarter of 2026. The primary driver of this loss was €3,032.07 in Cost of Goods Sold, which exceeded any recorded revenue for the period. Operating expenses totaled €1,194.45, representing a monthly burn rate of approximately €398. No sales income was recorded during Q1.
The company's cash position has deteriorated significantly year-over-year, declining from €532.14 to €116.00 (a 78.2% decrease). This decline is accompanied by a substantial increase in liabilities, which have grown from €14,949 to €36,056. The primary liability growth stems from director funding: Director's Current Account increased to €23,698 and Director's Loan Account to €12,550, suggesting reliance on director capital to fund ongoing operations.
At current burn rates, the remaining cash balance represents less than one week of operating runway. The business is not currently self-sustaining and requires either immediate revenue generation or additional capital injection. Net Assets stand at -€35,940, indicating the company is technically insolvent without continued director support.
Critical Alert
Cash reserves critically low. Immediate action required to secure funding or generate revenue.
Outstanding Receivables
€0.00
No outstanding customer invoices
Outstanding Payables
€0.00
All bills current
| Revenue | — |
| Cost of Goods Sold | (€3,032.07) |
| Gross Profit | (€3,032.07) |
| Operating Expenses | (€1,194.45) |
| — Consulting & Accounting | €613.00 |
| — Office: Software | €271.65 |
| — Research & Development | €191.98 |
| — Office Expenses | €53.47 |
| — Subscriptions | €42.36 |
| — Travel | €20.00 |
| — Bank Fees | €1.99 |
| Net Profit | (€4,226.52) |
Analyst Note
The consulting & accounting expense (€613) represents 51% of operating costs. With zero revenue recorded, this cost structure is unsustainable at current cash levels. Consider deferring non-essential professional fees or negotiating payment terms.
Largest Expense
Consulting & Accounting
€613.00
51.3% of OpEx
Total Monthly Avg
Operating Expenses
€398
per month
Total Assets
€116.00
↓ 78.2%
vs €532.14 in Q1 2025
Total Liabilities
€36,056
↑ 141%
vs €14,949 in Q1 2025
Net Assets
-€35,940
↑ 149%
vs -€14,417 in Q1 2025
Balance Sheet Analysis
Net Assets have deteriorated from -€14,417 to -€35,940, a 149% increase in deficit. The liability growth is primarily funded by director loans (€36,247 combined), indicating the business is dependent on director capital to continue operations. Current ratio is effectively zero given minimal cash reserves.
Accounts Receivable
Money owed to you
€0.00
All invoices paid
Status
No outstanding customer invoices
Accounts Payable
Money you owe
€0.00
Below prior year (€405.90)
Status
All supplier bills paid
Secure immediate funding or generate revenue
Current cash (€116) supports <1 week at current burn rate of €398/mo. Consider director loan increase, equity raise, or revenue-generating activities before end of March.
Review professional service costs
Consulting & accounting (€613, 51% of OpEx) is significant given no revenue. Evaluate necessity of these services or negotiate deferred payment terms until cash position improves.
Address negative equity position
Net assets of -€35,940 indicate insolvency. Consider formalizing director loans as equity conversion or additional capital injection to strengthen balance sheet.
Track monthly burn vs revenue
Establish weekly cash reporting. Target: reduce monthly burn to <€200 or generate revenue to cover expenses by Q2 end.
Report generated from Xero data on March 17, 2026
Alvio Labs | Confidential Management Report